Pompe Disease Treatment Market By Disease Type (Late-Onset Pompe Disease, Infantile-Onset Pompe Disease); By Treatment Type (Enzyme Replacement Therapy, Supportive and Symptomatic Treatment, Other Emerging Treatments); By Route of Administration (Intravenous, Oral); By End User (Hospitals, Specialty Clinics and Treatment Centers, Others); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Pompe Disease Treatment Market Size and Why Is Revenue Shifting Toward Newer ERTs?

The Global Pompe Disease Treatment Market was valued at USD 1.68 billion in 2025 and is projected to reach USD 2.51 billion by 2032, expanding at a CAGR of 5.9% during 2026–2032, according to Strategic Market Research.

 

Pompe disease treatment market is primarily driven by long-term enzyme replacement therapies (ERTs), and Pompe disease is a rare inherited lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA), resulting in glycogen accumulation in skeletal, respiratory, and cardiac muscles. Companies such as Sanofi and Amicus Therapeutics develop disease-modifying solutions targeting patient needs. Newborn screening data covering 11.6 million infants identified 621 confirmed cases, with an estimated birth prevalence of 1 in 18,711 births, including 85% late-onset and 15% infantile-onset cases.

 

The Pompe disease treatment market has evolved beyond the original single-ERT landscape, with multiple approved therapies offering differentiated treatment approaches. In the United States, Lumizyme (alglucosidase alfa) remains an established option, while Nexviazyme (avalglucosidase alfa-ngpt) targets patients aged 1 year and older with late-onset Pompe disease. Pombiliti (cipaglucosidase alfa-atga) with Opfolda (miglustat) provides an option for adults with LOPD who show inadequate response to current ERT.

 

The Pompe disease treatment market is segmented by disease subtype, with late-onset Pompe disease (LOPD) representing approximately 85% of diagnosed cases and driven by progressive skeletal muscle weakness and respiratory decline. LOPD patients retain 2%–40% residual GAA activity and have an estimated birth incidence of 1 in 21,902 births. Infantile-onset Pompe disease (IOPD) accounts for around 15% of cases, characterized by severe enzyme deficiency, cardiomyopathy, and early-life disease progression.

 

Pompe Disease Treatment Market Key Takeaways: Revenue Concentration, Patient Mix and Pipeline Upside

Disease Type

• Infantile-Onset Pompe Disease (IOPD) — 28.0% share and USD 0.47 billion in 2025; 4.8% CAGR. The segment is smaller by patient count but has high treatment urgency because early cardiac, respiratory and motor deterioration can make rapid therapy initiation clinically important.

• Late-Onset Pompe Disease (LOPD) — 72.0% share and USD 1.21 billion; 6.3% CAGR. LOPD is the main recurring revenue pool because it combines a larger identifiable patient base with years of chronic therapy and increasing treatment-switching options.

 

Treatment Type

• Enzyme Replacement Therapy (ERT) — 88.0% share and USD 1.48 billion; 5.5% CAGR. ERT remains the commercial backbone, but revenue is shifting from first-generation alglucosidase alfa toward newer enzyme products and switch-focused regimens.

• Supportive & Symptomatic Treatment — 7.0% share and USD 0.12 billion; 3.0% CAGR. The segment captures directly attributable treatment interventions used to manage respiratory, mobility, nutritional and other complications alongside disease-modifying therapy.

• Other/Emerging Treatments — 5.0% share and USD 0.08 billion; 14.4% CAGR. The 2025 figure is treated as a residual commercial treatment category; investigational gene, RNA, substrate-reduction and transport-enabled programs inform future upside rather than base-year revenue.

 

Route of Administration

• Intravenous — 94.0% share and USD 1.58 billion; 5.5% CAGR. The segment reflects the continued dominance of infusion-based ERT and the recurring administration model used by the principal marketed products.

• Oral — 6.0% share and USD 0.10 billion; 11.3% CAGR. Oral exposure is currently smaller and includes oral treatment components such as miglustat plus other monetized oral therapy within the SMR taxonomy; investigational oral substrate reduction represents a future catalyst rather than current commercial revenue.

 

End User

• Hospitals — 57.0% share and USD 0.96 billion in 2025; 5.2% CAGR. Hospitals remain central to diagnosis confirmation, treatment initiation, complex infusion management and care of clinically fragile IOPD patients.

• Specialty Clinics & Treatment Centers — 38.0% share and USD 0.64 billion; 7.1% CAGR. Their faster growth reflects the long-term, multidisciplinary management of LOPD and the need to monitor treatment response and switching decisions.

• Others — 5.0% share and USD 0.08 billion; 4.0% CAGR. This category includes home infusion, outpatient and other care settings used by clinically stable patients.

 

Geography

• North America — 42.0% share and USD 0.71 billion; 5.2% CAGR. Screening coverage, specialist infrastructure and access to multiple FDA-approved products support the largest regional revenue base.

• Europe — 30.0% share and USD 0.50 billion; 5.6% CAGR. National HTA decisions and negotiated access increasingly determine how rapidly newer ERT options replace legacy therapy.

• Asia Pacific — 20.0% share and USD 0.34 billion; 7.9% CAGR. Screening experience, improving specialist recognition and recent product approvals create the fastest regional growth profile.

• Latin America — 5.0% share and USD 0.08 billion; 6.0% CAGR. Expansion depends on specialist diagnosis and the ability of public and private systems to fund chronic high-cost biologics.

• Middle East & Africa — 3.0% share and USD 0.05 billion; 4.5% CAGR. Diagnosis, referral and infusion infrastructure remain the principal constraints on treatment conversion.

 

Newborn Screening Expands the Pompe Disease Treatment Market Funnel Without Immediate Revenue Conversion

Pompe market modelling is easier to understand when the commercial unit is viewed as a treated patient-year rather than as a prescription. The treatment pathway typically begins with newborn screening or symptoms that raise clinical suspicion, followed by biochemical and genetic confirmation, disease-subtype assessment, treatment eligibility, ERT initiation, long-term monitoring, and either continued treatment or a switch to another therapy. Based on approximately 4 million births in the United States each year, screening could identify around 40 infants with infantile-onset Pompe disease (IOPD) and approximately 94 infants with late-onset Pompe disease (LOPD) annually. However, not every identified patient immediately becomes a source of treatment revenue. Patients may remain undiagnosed, presymptomatic LOPD patients may be monitored without treatment, or reimbursement and access barriers may delay therapy initiation.

Newborn screening is becoming an important growth driver for the Pompe disease treatment market because it enables diagnosis before severe and irreversible muscle, respiratory, or cardiac damage develops. Pompe disease can progress rapidly in affected infants, making early identification critical for initiating enzyme replacement therapy (ERT) and other emerging treatments. In countries such as the United States, where newborn screening coverage is nearly universal and Pompe disease has been incorporated into screening programs in many states, more patients can be identified during the presymptomatic stage. Earlier diagnosis expands the addressable treatment population, increases treatment initiation rates, and can substantially extend the duration of therapy over a patient’s lifetime. Studies indicating significant gains in quality-adjusted life years from early treatment further support screening-based intervention.

However, global market penetration remains limited by unequal access to newborn screening. Of roughly 140 million babies born annually worldwide, only about 40 million are offered screening. Expansion of screening programs in Asia-Pacific, Latin America, the Middle East, and other underserved regions could therefore create substantial opportunities for Pompe disease drug manufacturers. At the same time, the high cost of lifelong therapy and unfavorable cost-effectiveness ratios may constrain reimbursement and adoption, particularly in lower-income healthcare systems.

In the United States, NewSTEPs reported that 48 state or territorial programs were performing population screening for Pompe, with 87% of newborns having access to universal screening as of February 28, 2025. The commercial effect depends on the disease subtype identified. IOPD can move rapidly from diagnosis to treatment because clinical deterioration may occur early and be severe. By contrast, many LOPD-positive newborns enter a monitoring pathway and may not require treatment for years. As a result, newborn screening expands the potential patient pool, but a positive screening result does not automatically translate into immediate treatment revenue. For market forecasting, screen-positive patients should therefore not be counted directly as treated patients; models should account for the time between diagnosis, treatment eligibility, therapy initiation, and long-term continuation.

IOPD accounted for 28.0% of the market in 2025 and is commercially important because of its high treatment urgency. Sanofi’s Phase III Baby-COMET study enrolled 17 treatment-naïve infants aged six months or younger and met its primary endpoint of survival without invasive ventilation at 52 weeks. Sanofi has stated that the results are intended to support a U.S. regulatory submission for IOPD; as of September 2026, that U.S. infantile indication remains investigational for Nexviazyme.

 

Late-Onset Pompe Disease Anchors Long-Duration Revenue and Treatment-Switch Economics

LOPD represented 72.0% of the Pompe Disease Treatment Market, equivalent to USD 1.21 billion in 2025, and is projected to grow at a CAGR of 6.3%. The segment combines a larger identifiable population with prolonged exposure to therapy after treatment initiation. It is also the phenotype in which competitive switching has become most visible because physicians can now choose among multiple ERT approaches and can reconsider treatment when functional or respiratory control is inadequate.

Long-term evidence explains why this switch opportunity exists without implying that conventional ERT “stops working” uniformly. In a prospective cohort of 30 adults followed for a median of 9.8 years on ERT, 93% showed an initial benefit, but 35% to 63% experienced secondary decline after roughly three to five years depending on the outcome measured. At ten years, 52% still had walking ability and/or upright lung function equal to or better than baseline. The market implication is not simple treatment failure; it is heterogeneous durability that creates space for products claiming better muscle delivery, stabilization or sustained activity.

Pombiliti plus Opfolda is commercially relevant because the FDA label directly targets adults with LOPD weighing at least 40 kg who are not improving on current ERT. FDA approval was based on a trial of 123 patients, 95 of whom had previously received ERT. This positions BioMarin’s acquired franchise inside the clinically important switching population rather than as a broad replacement for every newly diagnosed patient. Nexviazyme competes from a different position: it is an approved ERT for patients aged 1 year and older with LOPD and is designed with higher mannose-6-phosphate content to improve uptake into target cells.

 

Next-Generation ERTs Shift Share Inside the Pompe Disease Treatment Market

ERT accounted for 88.0% of the market, representing USD 1.48 billion in 2025, and is projected to expand at a CAGR of 5.5%. Its dominance is structurally durable through most of the forecast period because all currently scaled disease-modifying treatment revenue is still tied to enzyme replacement. The important change is occurring inside the category: share is migrating from legacy alglucosidase alfa toward newer enzyme products and combination approaches rather than away from ERT altogether.

Sanofi’s reported sales show that migration clearly. Nexviazyme/Nexviadyme generated €790 million in 2025, while the Myozyme/Lumizyme franchise generated €519 million. In the first half of 2026, Nexviazyme/Nexviadyme reached €426 million while Myozyme/Lumizyme fell to €220 million; Sanofi attributed the decline in the older franchise to the ongoing shift toward Nexviazyme/Nexviadyme. That transition is commercially important because it shows that meaningful market growth can come from product mix and switching even in a rare disease with a relatively stable incidence base.

Pombiliti plus Opfolda generated USD 112.5 million in 2025 before the Amicus acquisition. BioMarin completed the acquisition of Amicus on April 27, 2026, adding the two-component Pompe therapy to its lysosomal-disease portfolio. BioMarin reported USD 30.3 million of Pombiliti plus Opfolda revenue from the acquisition date through June 30, 2026. The combination uses cipaglucosidase alfa as the recombinant GAA enzyme while oral miglustat stabilizes the enzyme in circulation before cellular uptake. This creates a distinct commercial proposition focused on inadequate responders rather than simply another first-line infusion.

Supportive and symptomatic treatment represented 7.0% of the market, or USD 0.12 billion in 2025, and is forecast at a 3.0% CAGR. The segment is necessary because respiratory impairment, mobility loss, swallowing difficulties and nutritional issues are not completely eliminated by ERT. For consistency with the SMR scope, the segment should be interpreted as directly attributable treatment expenditure captured by the market taxonomy, not as the total economic burden of physiotherapy, ventilation, home care or diagnostic follow-up.

The supplied Other/Emerging Treatments segment accounted for 5.0%, or USD 0.08 billion in 2025, and carries the fastest treatment-type CAGR at 14.4%. The base-year value is retained as an SMR residual commercial category. It should not be presented as revenue from gene therapy, RNA therapy, DNL952, S-606001 or other investigational programs. Those assets explain why the category has strategic upside, but they remain outside current commercial product revenue until approval and launch.

 

Infusion Economics and Specialist Care Settings Define Pompe Disease Treatment Market Revenue Capture

Intravenous administration represented 94.0% of market value, or USD 1.58 billion in 2025, and is forecast to grow at a CAGR of 5.5%. This concentration reflects the administration model of the principal ERT products, which are typically given every other week. The route has commercial consequences beyond convenience: infusion capacity, treatment-center access, reimbursement coding and the ability to manage infusion-associated reactions all influence how a diagnosed patient converts into sustained therapy. CMS has established product-specific HCPCS coding for newer infused Pompe therapies, supporting claims processing and product identification in the U.S. reimbursement pathway.

Oral treatment represented 6.0% of the market, or USD 0.10 billion in 2025, and is projected to expand at an 11.3% CAGR. This does not mean Pompe treatment has already shifted to stand-alone oral disease modification. Opfolda is an oral component administered with intravenous Pombiliti, while the leading pure oral disease-modifying concept, S-606001, remains investigational. The route segment therefore captures monetized oral treatment components and other oral therapy within the SMR taxonomy, while future growth could accelerate if oral substrate reduction produces clinically meaningful add-on benefit.

Hospitals held 57.0% of the market, equivalent to USD 0.96 billion in 2025, and are projected to grow at 5.2%. Their position reflects confirmatory diagnosis, treatment initiation, management of severe IOPD and the infrastructure needed for complex biologic infusion. Specialty clinics and treatment centers accounted for 38.0%, or USD 0.64 billion, and carry the faster 7.1% CAGR because chronic LOPD management increasingly depends on neuromuscular, metabolic and respiratory expertise, particularly when patients are assessed for switching. Other settings, including home infusion and outpatient channels, represented 5.0%, or USD 0.08 billion, and are forecast at a 4.0% CAGR.

 

Regional Pompe Disease Treatment Market Value Follows Screening, Reimbursement and New-Therapy Access

North America accounted for 42.0% of the global market, representing USD 0.71 billion in 2025, and is projected to expand at a CAGR of 5.2%. The region combines broad newborn-screening access, specialist rare-disease infrastructure and multiple FDA-approved ERT options. NewSTEPs’ 87% newborn access to universal Pompe screening expands the identified patient funnel, while U.S. availability of Lumizyme, Nexviazyme and Pombiliti plus Opfolda makes treatment switching a more important commercial variable than basic access to ERT. BioMarin’s integration of the former Amicus franchise also adds greater commercial scale behind Pombiliti plus Opfolda in the region.

Europe held a 30.0% share, valued at USD 0.50 billion in 2025, and is expected to grow at a CAGR of 5.6%. The region has mature rare-disease centers but a fragmented reimbursement environment. NICE recommends both avalglucosidase alfa and cipaglucosidase alfa plus miglustat under commercial arrangements, while French early-access data show how national pathways can accelerate switching in defined populations. Commercial performance therefore depends on country-specific HTA and funding decisions rather than a single Europe-wide adoption curve.

Asia Pacific represented 20.0% of the market, equivalent to USD 0.34 billion in 2025, and is forecast to grow at the fastest regional CAGR of 7.9%. The region has contributed materially to the newborn-screening evidence base, and newer products are expanding beyond North America and Western Europe. Australia registered Pombiliti in February 2025 for use with miglustat in adults with LOPD, while Japan approved Pombiliti and Opfolda in June 2025. The combination of earlier recognition, expanding specialist capacity and wider product availability supports the region’s above-average forecast.

Latin America accounted for 5.0% of the market, representing USD 0.08 billion in 2025, and is projected to grow at a CAGR of 6.0%. The region’s opportunity is less about biological prevalence than conversion of diagnosed patients into sustained treatment. Specialist referral, public funding of rare-disease biologics, continuity of infusion supply and access to confirmatory genetic testing determine whether patients move from diagnosis into recurring ERT revenue.

The Middle East & Africa represented 3.0% of the market, valued at USD 0.05 billion in 2025, and are expected to grow at a CAGR of 4.5%. Treatment availability is concentrated in health systems with metabolic specialists, genetic confirmation and reliable infusion infrastructure. For manufacturers, the commercially addressable market is therefore likely to expand selectively through major treatment centers rather than uniformly across the region.

 

Sanofi and BioMarin Lead Marketed Pompe Therapy as New Modalities Broaden Competition

The competitive landscape is concentrated in marketed therapy but increasingly diversified in development strategy. Sanofi remains the incumbent commercial leader, BioMarin now owns the principal marketed challenger, and several biotechnology platforms are testing whether durable gene expression, substrate reduction or better tissue delivery can create clinically meaningful differentiation. The strongest competitive variables are treatment durability, skeletal-muscle and respiratory benefit, route and treatment burden, switch eligibility, payer acceptance and the ability to generate evidence that supports long-term reimbursement.

Sanofi

Sanofi’s relevant portfolio includes Myozyme/Lumizyme and Nexviazyme/Nexviadyme. Alglucosidase alfa established ERT as the treatment foundation, while avalglucosidase alfa is engineered with higher mannose-6-phosphate content to improve receptor-mediated cellular uptake. Commercially, the key story is portfolio migration: H1 2026 sales of Nexviazyme/Nexviadyme reached €426 million while Myozyme/Lumizyme fell to €220 million. Positive Baby-COMET data create the next potential growth leg because a U.S. IOPD label expansion would move the newer ERT earlier into the treatment pathway.

BioMarin Pharmaceutical

BioMarin became the owner of Pombiliti plus Opfolda after completing the Amicus acquisition in April 2026. The FDA-approved two-component regimen is positioned in adults with LOPD weighing at least 40 kg who are not improving on current ERT. This gives BioMarin a differentiated entry into the switch market rather than a broad undifferentiated ERT position. The acquired franchise also fits BioMarin’s existing rare-disease commercial infrastructure, which can support geographic expansion and payer engagement.

Astellas Pharma

Astellas is developing AT845 in the Phase I/II FORTIS program. The AAV8 gene therapy is designed to deliver a functional GAA gene directly to muscle and has FDA Regenerative Medicine Advanced Therapy designation. Five of six participants with at least one year of follow-up were reported off ERT for one to more than 3.5 years. The small dataset does not establish commercial viability, but the program is strategically important because durable ERT independence would change the lifetime revenue model for treated LOPD patients.

Bayer / AskBio

AskBio’s AB-1009 is an investigational AAV gene therapy in the recruiting Phase I/II PROGRESS-GT LOPD study. The first participant was dosed in May 2026 and the study is expected to enroll 12 adults in the United States. The program remains early, but it increases competitive pressure on the assumption that chronic enzyme replacement will remain the only scalable disease-modifying model.

Denali Therapeutics

Denali is developing DNL952, an investigational TransportVehicle-enabled GAA enzyme in Phase I. The program is designed to distribute enzyme to muscle while also crossing the blood-brain barrier. If clinical data eventually show meaningful benefit in tissues insufficiently addressed by conventional ERT, DNL952 could offer a lower-disruption switching option than one-time gene replacement while still differentiating on tissue delivery.

Shionogi / Maze Therapeutics

Shionogi is developing S-606001, formerly MZE001 from Maze Therapeutics, as an oral glycogen synthase 1 inhibitor. The randomized Phase II Esprit study is testing the drug as an add-on to ERT in adults with LOPD, and a Phase II extension study was posted in August 2026. The commercial relevance is the possibility of adding an oral mechanism that reduces glycogen production rather than competing only on enzyme replacement efficiency.

Aro Biotherapeutics

Aro’s ABX1100 is a muscle-targeted Centyrin-siRNA conjugate designed to reduce GYS1 expression and glycogen production. The Phase 1a/1b study is completed, with 46 total participants across healthy-volunteer and LOPD cohorts. The program remains early and unapproved, but it provides another substrate-reduction route that could eventually compete as an add-on or alternative to the current ERT model.

 

Analyst Commentary: Which Technologies and Medicines Could Drive the Next Breakthrough in Pompe Disease Treatment?

The next major breakthrough in the Pompe Disease Treatment Market is likely to come in stages rather than through an immediate replacement of enzyme replacement therapy. In the near term, Nexviazyme (avalglucosidase alfa) remains the strongest commercial catalyst because Sanofi is attempting to move the therapy earlier into the treatment pathway. Positive Phase III Baby-COMET results in infantile-onset Pompe disease could support a U.S. indication expansion, allowing Nexviazyme to compete more directly across both late-onset and infantile disease. This would accelerate the ongoing shift away from older alglucosidase alfa products while preserving the established infusion-based treatment model. Therefore, through the first part of the forecast period, improved ERT rather than gene therapy is likely to remain the largest source of incremental revenue.

Among emerging mechanisms, S-606001 could become one of the most commercially important new medicines if Phase II results validate glycogen synthase inhibition. Unlike therapies that attempt to improve enzyme delivery, S-606001 targets the production side of the disease by reducing glycogen synthesis in muscle. Its greatest commercial advantage is that it is being developed as an oral add-on to existing ERT. A successful outcome would therefore not immediately cannibalize current ERT revenue. Instead, it could create a new combination-treatment model in which patients receive both enzyme replacement and substrate reduction. This makes S-606001 particularly attractive from a market-growth perspective because it could increase revenue per treated patient while offering physicians another option for patients showing incomplete response to ERT.

The most disruptive technology, however, is AAV gene therapy, with Astellas' AT845 currently providing one of the strongest early clinical signals. The program aims to establish sustained GAA production in skeletal muscle after a single administration. Early company-reported evidence showing several patients remaining off ERT for extended periods is strategically important because it suggests that durable treatment independence may be biologically possible. If this effect is confirmed in larger trials with acceptable safety and durability, AT845 could fundamentally alter the lifetime economics of Pompe disease. Instead of years of biweekly infusions, a subset of patients could potentially receive a one-time treatment. Bayer/AskBio's AB-1009 is pursuing a similar gene-replacement opportunity, although it remains earlier in human development and currently carries greater clinical uncertainty.

Another technology worth watching closely is Denali's DNL952 TransportVehicle-enabled enzyme platform. Its importance is different from gene therapy. DNL952 seeks to improve the distribution of GAA into muscle while also enabling transport across the blood-brain barrier. If successful, this could create a new generation of ERT with broader tissue penetration while avoiding some of the eligibility, durability and safety uncertainties associated with AAV-based gene replacement. Meanwhile, Aro Biotherapeutics' ABX1100, which uses muscle-targeted siRNA to suppress GYS1, could provide another route to substrate reduction. Both technologies remain early, but they represent important attempts to address limitations that conventional ERT cannot fully overcome.

 

Pompe Disease Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 1.68 Billion
Revenue Forecast in 2032	USD 2.51 Billion
Overall Growth Rate	5.9% CAGR
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion
Segmentation	Disease Type; Treatment Type; Route of Administration; End User; Geography
By Disease Type	Infantile-Onset Pompe Disease; Late-Onset Pompe Disease
By Treatment Type	Enzyme Replacement Therapy; Supportive & Symptomatic Treatment; Other/Emerging Treatments
By Route of Administration	Intravenous; Oral
By End User	Hospitals; Specialty Clinics & Treatment Centers; Others
By Region	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope	United States, Canada, Mexico, Germany, France, United Kingdom, Italy, Spain, Netherlands, China, Japan, India, South Korea, Australia, Brazil, Argentina, GCC Countries, South Africa and Rest of World
Market Drivers	Newborn screening expansion, long-term ERT use, newer ERT switching, rare-disease diagnosis, additional regional approvals, oral substrate-reduction development and gene-therapy investment
Customization Option	Available upon request